Efficacy and safety of FangJiHuangQi granule in patients with heart failure: a protocol of randomized, placebo-controlled trial - Takeaways - MDSpire

Efficacy and safety of FangJiHuangQi granule in patients with heart failure: a protocol of randomized, placebo-controlled trial

  • By

  • Deng Pan

  • Lu Liang

  • Qian Zhao

  • Jianwu Zheng

  • Houyong Zhu

  • Yu Wang

  • Cheng Bao

  • Tielong Chen

  • May 29, 2026

  • 0 min

Share

  • 1

    FangJiHuangQi Granules (FJHQG) are a Chinese patent medicine aimed at alleviating heart failure symptoms.

  • 2

    The trial is a randomized, double-blind, placebo-controlled study involving 100 heart failure patients.

  • 3

    Primary outcome measures include changes in the six-minute walk test after 24 weeks of treatment.

  • 4

    Secondary outcomes include BNP levels, NYHA classification, major adverse cardiovascular events, and quality of life scales.

  • 5

    The study aims to evaluate the efficacy and safety of FJHQG as a complementary therapy to conventional treatments.

Original Source(s)

Efficacy and safety of FangJiHuangQi granule in patients with heart failure: a protocol of randomized, placebo-controlled trial

  • by Deng Pan, Lu Liang, Qian Zhao, Jianwu Zheng, Houyong Zhu, Yu Wang, Cheng Bao, Tielong Chen

  • May 29, 2026

Related Content

Prognostic value of CTI for major adverse cardiovascular events in patients With ST-elevation myocardial infarction after primary percutaneous coronary intervention

Global evidence on the cost-effectiveness of cardiac resynchronization therapy for heart failure: a systematic review

Residual risk in cardiovascular and renal diseases and the potential role of aldosterone synthase inhibitors